Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Efficacy of Adoptive Immunotherapy By Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation from Related an Unrelated Donors: A Single Center Retrospective Analysis

Philipp Hemmati, MD, Christin Vogelsänger, Theis Terwey, MD, Christian Jehn, MD, Lam G. Vuong, MD PhD, Igor Wolfgang Blau, MD, Olaf Penack, MD, Bernd Dörken, Renate Arnold, MD PhD

Blood (2016) 128 (22): 4556.

https://doi.org/10.1182/blood.V128.22.4556.4556

Published: 2016

Journal Articles

Grouping of Genetic Risk By the European Leukemia Net Classification Predicts Overall Survival and Relapse Incidence in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Philipp G. Hemmati, MD, Theis Terwey, MD, Il-Kang Na, MD, Christian Jehn, MD, Lam G. Vuong, PhD, Philipp le Coutre, MD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2015) 126 (23): 2012.

https://doi.org/10.1182/blood.V126.23.2012.2012

Published: 2015

Journal Articles

Achieving Early Remission By Induction Therapy Predicts a Favorable Outcome in Patients with Acute Myeloid Leukemia and an Intermediate Risk Karyotype Undergoing Allogeneic Stem Cell Transplantation in First Complete Remission

Philipp G. Hemmati, MD, Theis H. Terwey, MD, Il-Kang Na, MD, Philipp le Coutre, MD, Christian F. Jehn, MD, Lam G. Vuong, PhD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2014) 124 (21): 2569.

https://doi.org/10.1182/blood.V124.21.2569.2569

Published: 2014

Journal Articles

Allogeneic Stem Cell Transplantation For Cytogenetically Normal Acute Myeloid Leukemia: Impact Of FLT3 and NPM1 Mutational Status

Philipp Hemmati, MD, Theis H. Terwey, MD, Lam G. Vuong, PhD, Philipp D le Coutre, MD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2013) 122 (21): 2104.

https://doi.org/10.1182/blood.V122.21.2104.2104

Published: 2013

Journal Articles

NIH-Defined Graft-Versus-Host Disease in Patients with Acute Lymphoblastic Leukemia: Natural History, Prognostic Impact and Effect of Donor Lymphocyte Infusions

Theis H. Terwey, Tanja M. Le Duc, Philipp G. Hemmati, Lam G. Vuong, Peter Martus, Philipp D. le Coutre, MD, Bernd Dörken, Renate Arnold

Blood (2011) 118 (21): 4547.

https://doi.org/10.1182/blood.V118.21.4547.4547

Published: 2011

Journal Articles

Natural History, Risk Factors and Prognostic Impact of Graft-Versus-Host Disease Classified According to the National Institute of Health Criteria in Patients Receiving Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Theis H Terwey, Arturo Vega-Ruiz, Philipp G. Hemmati, Peter Martus, Ekkehart Dietz, Lam G Vuong, Philipp D le Coutre, Bernd Dörken, Renate Arnold

Blood (2010) 116 (21): 899.

https://doi.org/10.1182/blood.V116.21.899.899

Published: 2010

Journal Articles

Allogeneic Stem Cell Transplantation for Secondary or Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome with Poor-Risk Cytogenetics.

Philipp G. Hemmati, MD, Theis Terwey, MD, Philipp D. le Coutre, MD, Gero Massenkeil, MD, Lam G Vuong, MD, PhD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2010) 116 (21): 3470.

https://doi.org/10.1182/blood.V116.21.3470.3470

Published: 2010

Journal Articles

Incidence and Clinical Characteristics of Chronic Graft Versus Host Disease (cGVHD) According to the National Institutes of Health (NIH) Criteria in Patients Transplanted for Acute Myeloid Leukemia (AML).

Arturo Vega, Peter Martus, Theis Terwey, Christian Jakob, MD, Lam G Vuong, Philipp Hemmati, Philipp D. le Coutre, MD, Renate Arnold, MD

Blood (2009) 114 (22): 4639.

https://doi.org/10.1182/blood.V114.22.4639.4639

Published: 2009

Journal Articles

Pre-Transplant Risk-Assessment for Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplants.

Philipp G. Hemmati, MD, Theis H. Terwey, MD, Philipp le Coutre, MD, Gero Massenkeil, MD, Lam G Vuong, PhD, Christian Jakob, MD, Arturo Vega, MD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2009) 114 (22): 2302.

https://doi.org/10.1182/blood.V114.22.2302.2302

Published: 2009

Journal Articles

Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Combined with Leukemic Risk Factors Predict Outcome of AML Patients after Allogeneic Stem Cell Transplantation Following Reduced Intensity Conditioning (RIC).

Philipp Hemmati, Theis Terwey, Gero Massenkeil, MD, Philipp D. le Coutre, MD, Stefan Neuburger, Lam G Vuong, Bernd Dörken, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 3276.

https://doi.org/10.1182/blood.V112.11.3276.3276

Published: 2008

Journal Articles

Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation in AML Patients with An Intermediate Risk Karyotype: No Difference in Outcome as Compared to Standard Myeloablative Conditioning (MAC).

Philipp Hemmati, Gero Massenkeil, MD, Theis Terwey, Stefan Neuburger, Philipp D. le Coutre, MD, Lam G Vuong, Bernd Dörken, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 3278.

https://doi.org/10.1182/blood.V112.11.3278.3278

Published: 2008

NARROW

Efficacy of Adoptive Immunotherapy By Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation from Related an Unrelated Donors: A Single Center Retrospective Analysis

Grouping of Genetic Risk By the European Leukemia Net Classification Predicts Overall Survival and Relapse Incidence in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Achieving Early Remission By Induction Therapy Predicts a Favorable Outcome in Patients with Acute Myeloid Leukemia and an Intermediate Risk Karyotype Undergoing Allogeneic Stem Cell Transplantation in First Complete Remission

Allogeneic Stem Cell Transplantation For Cytogenetically Normal Acute Myeloid Leukemia: Impact Of FLT3 and NPM1 Mutational Status

NIH-Defined Graft-Versus-Host Disease in Patients with Acute Lymphoblastic Leukemia: Natural History, Prognostic Impact and Effect of Donor Lymphocyte Infusions

Natural History, Risk Factors and Prognostic Impact of Graft-Versus-Host Disease Classified According to the National Institute of Health Criteria in Patients Receiving Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Allogeneic Stem Cell Transplantation for Secondary or Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome with Poor-Risk Cytogenetics.

Incidence and Clinical Characteristics of Chronic Graft Versus Host Disease (cGVHD) According to the National Institutes of Health (NIH) Criteria in Patients Transplanted for Acute Myeloid Leukemia (AML).

Pre-Transplant Risk-Assessment for Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplants.

Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Combined with Leukemic Risk Factors Predict Outcome of AML Patients after Allogeneic Stem Cell Transplantation Following Reduced Intensity Conditioning (RIC).

Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation in AML Patients with An Intermediate Risk Karyotype: No Difference in Outcome as Compared to Standard Myeloablative Conditioning (MAC).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only